Study Details

Back to Search Results

A study of ASP2138 in adults with stomach cancer, gastroesophageal junction cancer, pancreatic cancer

This trial is recruiting
The study is currently recruiting participants.

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT05365581

Astellas Study ID

The unique identification code given by the study sponsor.

2138-CL-0101

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Stomach or Esophageal Cancer, Pancreatic Cancer

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

18 Years - N/A

Sex

Female & Male

Product

ASP2138

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Jun 2022 - Dec 2025

Masking

None (Open Label)

Enrollment number

240

A Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A study of ASP2138 in adults with stomach cancer, gastroesophageal junction cancer, pancreatic cancer? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

National Cancer Center Hospital East

Kashiwa, Japan

Recruiting
Contact Us

National Cancer Center Hospital

Chuo-ku, Japan

Recruiting
Contact Us

The Cancer Institute Hospital of Japanese Foundation for Cancer Research

Koto-ku, Japan

Recruiting
Contact Us

Aichi Cancer Center

Nagoya, Japan

Recruiting
Contact Us

Kanagawa Cancer Center

Yokohama, Japan

Recruiting
Contact Us

UCLA Dept of Medicine – Hematology/Oncology, Santa Monica

Santa Monica, United States, 90404

Recruiting
Contact Us

UT Southwestern Medical Center

Dallas, United States, 75390

Recruiting
Contact Us

Froedtert Hospital and the Medical College of Wisconsin

Milwaukee, United States, 53226

Recruiting
Contact Us

Virginia Mason Medical Center

Seattle, United States, 98101

Recruiting
Contact Us

Site KR82002

Jongno-gu, Republic of Korea

Recruiting
Contact Us

Site KR82004

Seongnam-si, Republic of Korea

Recruiting
Contact Us

Site KR82001

Guro-gu, Republic of Korea

Recruiting
Contact Us

Site KR82005

Seodaemun-gu, Republic of Korea

Recruiting
Contact Us

Memorial Sloan Kettering Cancer Center

New York, United States, 10065

Recruiting
Contact Us

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo